After the Kefauver Harris Amendment was passed in 1962, the . FDA began the DESI review process to ensure the safety and efficacy of drugs approved under the more lenient pre-1962 standards, including Dianabol.  In 1965, the FDA pressured CIBA to further document its legitimate medical uses, and re-approved the drug for treating post-menopausal osteoporosis and pituitary-deficient dwarfism .  After CIBA's patent exclusivity period lapsed, other manufacturers began to market generic metandienone in the .
By understanding the detection times of steroids we greatly improve our odds in beating a steroid test but there are also other things to consider. Steroid testing has over the years become more comprehensive, but the manufactures of anabolic hormones seem to stay a step ahead of testing, and year after year new compounds and mixtures come out that allow the athlete to beat the test; again, recall BALCO from the early to mid-2000's. While these designer steroids continue to pop up, eventually steroid testing catches up too only to find a new designer steroid has taken its place. Then of course we have performance enhancing drugs of a non-steroidal nature that are undetectable to such testing; most notably Human Growth Hormone (HGH) a peptide hormone that is undetectable. More and more athletes are now supplementing with many of these undetectable performance enhancing drugs and beating the fight against them each and every day.